We engineered CD8+ T cells with two orthogonal cytokines for adoptive cell transfer into mice with solid tumors. These cells acquired a novel synthetic effector state that fully deviated from TOX+ canonical exhaustion and displayed improved anti-tumor effector functions.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hashimoto, M. et al. PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature 610, 173–181 (2022). A fundamental study defining the mechanisms by which IL-2 acts in synergy with PD-1 blockade to modify CD8+ T cell exhaustion.
Codarri Deak, L. et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature 610, 161–172 (2022). A seminal study demonstrating the generation of non-canonical improved effector cells after systemic administration of anti-PD-1–IL-2v treatment.
Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211–218 (2019). A seminal study demonstrating that TOX is the transcriptional and epigenetic master regulator of CD8+ T cell exhaustion.
Carmenate, T. et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J. Immunol. 190, 6230–6238 (2013). Outstanding work demonstrating the anti-tumor efficacy of systemic administration of IL-2v.
Villarreal, D. O. et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res. 74, 1789–1800 (2014). Outstanding work demonstrating that IL-33 can be an effective adjuvant to drive CD8-mediated protective immunity against cancer.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Corria-Osorio, J. et al. Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells. Nat. Immunol. https://doi.org/10.1038/s41590-023-01477-2 (2023).
Rights and permissions
About this article
Cite this article
Generation of a novel synthetic CD8+ T cell state that leads to tumor control in mice. Nat Immunol 24, 755–756 (2023). https://doi.org/10.1038/s41590-023-01478-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-023-01478-1
